AIMT Mid-Q1 '19 Update


AIMT has been effected by the FDA partial shutdown, which is a reason it is up less than 3% thus far this year. This is exacerbated by an apparent disagreement with the FDA regarding the proper classification for its peanut allergy desensitization treatment regulatory approval filing. This puts some downside risk on AIMT in the short-term as the FDA may determine that AIMT filed for approval using the wrong BLA category. If so, AIMT will need to refile, which will delay a decision by the FDA. However, we are still very bullish on AIMT with a 1 or 2 year time frame. They have established themselves as the future market leader in peanut allergy desensitization technology.


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon